Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study)

[11] Seshiah V(2016)Safety and tolerability of empagliflozin in patients with type 2 diabetes Clin Ther 38 1299-862

[12] Swallow R(2016)Efficacy and safety of the SGLT2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus stratified according to baseline body mass index: pooled analysis of data from 52-week phase III trials Clin Ther 38 843-1255

[13] Jones R(2014)Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study Curr Med Res Opin 30 1245-1407

[14] Rattunde H(2017)Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): results of a 16-week randomized, double-blind, placebo-controlled multicentre trial Diabetes Obes Metab 19 1397-471

[15] Woerle HJ(2016)Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): interim results of a post-marketing surveillance study Expert Opin Pharmacother 17 463-665

[16] Gallo LA(2016)Efficacy and safety of canagliflozin in patients with type 2 diabetes: a meta-analysis of randomized controlled trials Medicine. 95 e5473-178

[17] Wright EM(2015)Review of patient-reported outcome instruments measuring health-related quality of life and satisfaction in patients with type 2 diabetes treated with oral therapy Curr Med Res Opin 31 643-1307

[18] Vallon V(2008)Improvement of glycemic control and quality-of-life by insulin lispro therapy: assessing benefits by ITR-QOL questionnaires Diabetes Res Clin Pract 81 169-558

[19] Zinman B(2016)Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors Patient Prefer Adherence. 10 1299-892

[20] Wanner C(2013)The prevalence of hypoglycemia and its impact on the quality of life (QoL) of type 2 diabetes mellitus patients (The HYPO Study) Hormones. 12 550-1207

[11] Seshiah V(2016)Safety and tolerability of empagliflozin in patients with type 2 diabetes Clin Ther 38 1299-862

[12] Swallow R(2016)Efficacy and safety of the SGLT2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus stratified according to baseline body mass index: pooled analysis of data from 52-week phase III trials Clin Ther 38 843-1255

[13] Jones R(2014)Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study Curr Med Res Opin 30 1245-1407

[14] Rattunde H(2017)Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): results of a 16-week randomized, double-blind, placebo-controlled multicentre trial Diabetes Obes Metab 19 1397-471

[15] Woerle HJ(2016)Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): interim results of a post-marketing surveillance study Expert Opin Pharmacother 17 463-665

[16] Gallo LA(2016)Efficacy and safety of canagliflozin in patients with type 2 diabetes: a meta-analysis of randomized controlled trials Medicine. 95 e5473-178

[17] Wright EM(2015)Review of patient-reported outcome instruments measuring health-related quality of life and satisfaction in patients with type 2 diabetes treated with oral therapy Curr Med Res Opin 31 643-1307

[18] Vallon V(2008)Improvement of glycemic control and quality-of-life by insulin lispro therapy: assessing benefits by ITR-QOL questionnaires Diabetes Res Clin Pract 81 169-558

[19] Zinman B(2016)Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors Patient Prefer Adherence. 10 1299-892

[20] Wanner C(2013)The prevalence of hypoglycemia and its impact on the quality of life (QoL) of type 2 diabetes mellitus patients (The HYPO Study) Hormones. 12 550-1207